Summarized by Masters of Longevity from PR Newswire.
A news article previewing detailed Phase 3 trial results for an oral diabetes drug, highlighting cardiometabolic outcomes and clinical implications for care.
Key Takeaways
- Foundayo reduced the composite MACE-4 risk by 16% versus insulin glargine with a hazard ratio of 0.84.
- Foundayo lowered A1C and produced mean waist circumference and systolic blood pressure reductions at week 52.
- Foundayo was linked to 53% lower cardiovascular death and 57% lower all-cause death in pre-planned analyses.
